Beauty is only skin deep, or so the old adage goes. However, dietary and lifestyle choices can affect physical wellbeing, including the characteristics that are associated with ‘beauty’.
Then, there are genetic disorders such as male pattern baldness. This not so hairy problem has created a market for cosmetic products that can help combat hair loss.
Not only that, but there are currently FDA approved products for eyelash lengthening and thickening too!
If you’re researching for potent chemicals to combat hair loss, you must have come across the synthetic prostaglandin analog Bimatoprost. Once it was shown to work for eyelashes, the interest in this analog further grew for potential efficacy against baldness.
Allergan’s LatisseÒ¾FDA approved treatment
A number of restoration treatments, including transplants and topical medications are available to address baldness. However, none of them are very effective and most require long term treatment. Also, these are extremely expensive and out of the reach of most of the affected individuals.
When Latisse was approved for eyelash growth by Food and Drug Administration (FDA), it was thought that similar efficacy would be observed for scalp hair growth. However, this did not happen, leading to researchers going back to their labs to find another solution.
Allergan started clinical trials in 2011 to determine if the product will be effective against scalp hair loss. The results obtained from the clinical trials were inconclusive. This suggested that Latisse may not work as effectively to treat baldness.
Researching alternatives
Bimatoprost, the active ingredient of Latisse, is a synthetic prostaglandin analog for FP receptor. It was initially approved for glaucoma and a different formulation was subsequently approved for cosmetic purposes.
Recently, regulations have been tightening around eyelash enhancing products due to their potential side effects. Bimatoprost based drug can cause permanent iris darkening and reversible eyelid skin darkening, among other side effects. It may potentially be banned or users may be discouraged to purchase the drug in several European countries.
Several industrial and academic labs are trying to find an alternative for Bimatoprost. Obvious choices that are under study include Cloprostenol isopropyl ester and Methylamido dihydro noralfaprostal (MDN).
MDN is similar in both form and function, while CIE is only similar in eyelash lengthening function to Bimatoprost. These studies may even offer insight as to their use against scalp baldness.
If you want a competitive advantage, order high purity prostaglandin analogs from Watson International. They are one of the few mature manufactures of synthetic analogs, supplying these and other reagents to labs around the world.
Contact the company for more details about their products or visit the links below:
Cloprostenol isopropyl ester: http://watson-int.com/cloprostenol-isopropyl-ester-cas-157283-66-4cloprostenol-isopropyl-ester-cas-157283-66-4/
Methylamido dihydro Noralfaprostal: http://watson-int.com/methylamido-dihydro-noralfaprostal-cas-155206-01-2/
Bimatoprost: http://watson-int.com/bimatoprost-cas-155206-00-1/
Then, there are genetic disorders such as male pattern baldness. This not so hairy problem has created a market for cosmetic products that can help combat hair loss.
Not only that, but there are currently FDA approved products for eyelash lengthening and thickening too!
If you’re researching for potent chemicals to combat hair loss, you must have come across the synthetic prostaglandin analog Bimatoprost. Once it was shown to work for eyelashes, the interest in this analog further grew for potential efficacy against baldness.
Allergan’s LatisseÒ¾FDA approved treatment
A number of restoration treatments, including transplants and topical medications are available to address baldness. However, none of them are very effective and most require long term treatment. Also, these are extremely expensive and out of the reach of most of the affected individuals.
When Latisse was approved for eyelash growth by Food and Drug Administration (FDA), it was thought that similar efficacy would be observed for scalp hair growth. However, this did not happen, leading to researchers going back to their labs to find another solution.
Allergan started clinical trials in 2011 to determine if the product will be effective against scalp hair loss. The results obtained from the clinical trials were inconclusive. This suggested that Latisse may not work as effectively to treat baldness.
Researching alternatives
Bimatoprost, the active ingredient of Latisse, is a synthetic prostaglandin analog for FP receptor. It was initially approved for glaucoma and a different formulation was subsequently approved for cosmetic purposes.
Recently, regulations have been tightening around eyelash enhancing products due to their potential side effects. Bimatoprost based drug can cause permanent iris darkening and reversible eyelid skin darkening, among other side effects. It may potentially be banned or users may be discouraged to purchase the drug in several European countries.
Several industrial and academic labs are trying to find an alternative for Bimatoprost. Obvious choices that are under study include Cloprostenol isopropyl ester and Methylamido dihydro noralfaprostal (MDN).
MDN is similar in both form and function, while CIE is only similar in eyelash lengthening function to Bimatoprost. These studies may even offer insight as to their use against scalp baldness.
If you want a competitive advantage, order high purity prostaglandin analogs from Watson International. They are one of the few mature manufactures of synthetic analogs, supplying these and other reagents to labs around the world.
Contact the company for more details about their products or visit the links below:
Cloprostenol isopropyl ester: http://watson-int.com/cloprostenol-isopropyl-ester-cas-157283-66-4cloprostenol-isopropyl-ester-cas-157283-66-4/
Methylamido dihydro Noralfaprostal: http://watson-int.com/methylamido-dihydro-noralfaprostal-cas-155206-01-2/
Bimatoprost: http://watson-int.com/bimatoprost-cas-155206-00-1/
